Immago is developing innovations in the field of therapeutic antibodies arising from
work in the Glycobiology Institute of the University of Oxford.
With our technology we seek to enable a new generation of cancer therapies by enhancing
the efficacy of therapeutic monoclonal antibodies (mAbs).
Working with partners, we aim to develop better anti-cancer therapies, by improving
the efficacy of existing and abandoned mAbs, and developing novel mAbs taking advantage
of our unique knowledge of the field of therapeutic glycoproteins.